In preclinical NB models SGSS05-NS3 treatment was firstly performed ex-vivo, since animal toxicology and bioavailability of SGSS05-NS3 compound did not allow continuous in vivo treatment of mice with this SETD8 inhibitor. This evidence concerns the gene KMT5A and neuroblastoma.